Table 1.

Patients’ demographic and clinical features (SD, standard deviation; F, female; n.s., not significant; n.a., not applicable, ANA, anti-nuclear antibodies).

First phase of the study				Second phase of the study
	pSS (n=82)	HC (n=29)	p-value	pSS (n=30)	HC (n=15)	Non-SS (n=12)	p-value
Sex	82F	29F		30F	15F	12F
Age at the inclusion (yrs), mean (SD)	54.6 (13.8)	53.2 (12.8)	n.s.	53.9 (12.7)	52.6 (12.4)	54.0 (13.4)	n.s.
Salivary flow rate ml/15’ (median and interquartile) (mean(SD))	2(1.1 to 4.125)3.0(2.7)	4.15(2.5 to 7.875)5.3(3.7)	0.005	2.5(1.5 to 4.25)	5.5(4.2 to 10)5.1(4.2)	3(2.1 to 6.75)6.6(3.1)	0.013
Focus score (high/low)	20/50	n.a.	n.a.	7/16	n.a.	n.a.	n.a.
ANA (%)	100	n.a.	n.a.	100	n.a.	58	0.0009
Anti-Ro/SSA (%)	57.3	n.a.	n.a.	60	n.a.	n.a.	n.a.
Anti-La/SSB (%)	22	n.a.	n.a.	18	n.a.	n.a.	n.a.
Rheumatoid Factor (%)	43	n.a.	n.a	43	n.a.	n.a.	n.a.